Meridian Clinical Research, LLC

Binghamton, New York 13905

0 studies enrolling now · 12 studies all time

What they study most

COVID-19, Cardiovascular Diseases, Chronic Kidney Disease, Clostridium Difficile Infection, Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention, Lyme Borreliosis, Meningococcal Vaccine, Obesity, Overweight, Overweight or Obesity, Pneumococcal Disease, SARS-CoV-2 Infection

Studies at this site

• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Completed
• Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children — Completed
• Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age. — Completed
• Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age — Completed
• A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. — Completed
• MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age — Completed
• Clostridium Difficile Vaccine Efficacy Trial — Completed
• Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age — Completed